MK-2206, an allosteric AKT Inhibitor, showed synergistic responses in combination with carboplatin in lung and ovarian cancer cells while targeting Akt/mTOR axis via ABTL0812 significantly potentiated cisplatin anti-tumor activity in nude mice of lung cancer [29,30]. This evidence concerns the gene AKT1 and ovarian carcinoma.